Handbook of Pharmaceutical Manufacturing Formulations, Third Edition (3^rd Ed.) Volume Two, Uncompressed Solid Products

The Handbook of Pharmaceutical Manufacturing Formulations, Third Edition: Volume Two, Uncompressed Solid Products is an authoritative and practical guide to the art and science of formulating drugs for commercial manufacturing. With thoroughly revised and expanded content, this second volume of a six-volume set, compiles data from FDA and EMA new drug applications, patents and patent applications, and other sources of generic and proprietary formulations including author?s own experience, to cover the broad spectrum of cGMP formulations and issues in using these formulations in a commercial setting. A must-have collection for pharmaceutical manufacturers, educational institutions, and regulatory authorities, this is an excellent platform for drug companies to benchmark their products and for generic companies to formulate drugs coming off patent.

Features:

Largest source of authoritative and practical formulations, cGMP compliance guidance and self-audit suggestions

Differs from other publications on formulation science in that it focuses on readily scalable commercial formulations that can be adopted for cGMP manufacturing

Tackles common difficulties in formulating drugs and presents details on stability testing, bioequivalence testing, and full compliance with drug product safety elements

Written by a well-recognized authority on drug and dosage form development including biological drugs and alternative medicines

Part I. Regulatory and Manufacturing Guidelines

Chapter 1. U.S. FDA Good Manufacturing Practices

Chapter 2. Guideline on the Common Technical Document for the Registration of Pharmaceuticals for Human Use

Chapter 3. Process Validation: General Principles and Practices

Chapter 4. Bioequivalence Regulatory Compliance

Chapter 5. Bioequivalence Regulatory Review Process and Audit

Chapter 6. EU Guidelines to Good Manufacturing Practice: Active Drug Substance

Chapter 7. FDA Pre-approval Inspections

Chapter 8. Formulation Factors in Uncompressed Dosage Forms

Chapter 9: Solid-State Properties.

Chapter 10: Formulation of Flavor.

Part II. Manufacturing Formulations

Uncompressed Solids Formulations

Part III. Commercial Pharmaceutical Formulations.

Commercial Pharmaceutical Formulations.

Sarfaraz K. Niazi, Ph.D., a well-recognized authority on drug and dosage form development including biological drugs and alternative medicines. He is Founder and Executive Chairman of Adello Biologics, LLC, (formerly, Therapeutic Proteins International, LLC), a biosimilar products company located in Chicago, IL, Piscataway, NJ and Cashel, Ireland. As an entrepreneur, Niazi has raised hundreds of millions of dollars and became recognized as an inductee into the Chicago Entrepreneur Hall of Fame.Niazi began his career teaching pharmaceutical sciences at the University of Illinois, College of Pharmacy where he was tenured before entering the industry at Abbott International. He departed Abbott as an Abbott Volwiler Fellow to pursue his passion, first through global consulting and later through the founding a biosimilar products company.

A prolific inventor with scores of patents, most prominently in the field of bioprocessing technology, Niazi is currently the largest single holder of bioprocess technology patents. His other inventions span a broad category of technologies, new chemical entities, new formulations, new analytical methodologies, and much more. He has hands on experience in developing chemical, botanical and biological products, from discovery to regulatory approval. With over 50 ISBNs under his name, Niazi has authored many landmark books in the field of pharmaceutical sciences.

He currently serves as Adjunct Professor at the University of Illinois College of Pharmacy, Ad Hoc faculty at the University of Houston, Texas, the HEJ Research Institute, Karachi, and the National University of Science and Technology, Islamabad. He has also served as a Foreign Professor at the HEJ Research Institute, Karachi. He serves on the editorial board of the journal MOJ Proteomics & Bioinformatics (MOJPB) and starting 2017, as Chief Editor of International Journal of Biosimilars. He also serves as Member of National